Crystalline forms and salt forms of a kinase inhibitor
AssigneeExelixis, Inc.
InventorsFrenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
Life of this patent
Estimating the term…
Abstract
The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
Claims11
A crystalline hemifumarate Form B of Compound 1 having the structure
A Compound 1 hemifumarate having the structure
- wherein said Compound 1 hemifumarate is in crystalline Form B and said Form B is characterized by an X-ray powder diffraction pattern comprising peaks at 9.08, 16.95, 19.16, and 26.34 degrees 2θ (±0.20 degrees).
A Compound 1 hemifumarate having the structure
- wherein said Compound 1 hemifumarate is in crystalline Form B and said Form B is characterized by an X-ray powder diffraction pattern substantially as depicted in FIG. 29.
Dependencies are inferred from the claim text.